{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:31:52Z","timestamp":1790332312308,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.diabet.2026.101744","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T16:07:52Z","timestamp":1772294872000},"page":"101744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Severe hyperglycemia after initiation of long-acting cabotegravir in two antiretroviral treatment-controlled people with HIV"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-1195","authenticated-orcid":false,"given":"Nadia","family":"Valin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Campa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Chiarabini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Collet-Gaudillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Kury Paulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Capeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2026.101744_bib0001","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1403","article-title":"Risk of incident diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with human immunodeficiency virus in the United States and Canada","volume":"73","author":"Rebeiro","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diabet.2026.101744_bib0002","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/cid\/ciac355","article-title":"Integrase strand transfer inhibitors are associated with incident diabetes mellitus in people with human immunodeficiency virus","volume":"75","author":"O'Halloran","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diabet.2026.101744_bib0003","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/hiv.13698","article-title":"Dat'AIDS study group. increased incidence of diabetes in people living with HIV treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study","volume":"26","author":"Ursenbach","year":"2025","journal-title":"HIV Med"},{"key":"10.1016\/j.diabet.2026.101744_bib0004","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1097\/QAD.0000000000003954","article-title":"Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV","volume":"38","author":"Hwang","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.diabet.2026.101744_bib0005","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/cid\/ciae406","article-title":"Integrase strand transfer inhibitor-related changes in body mass index and risk of diabetes: a prospective study from the RESPOND Cohort Consortium","volume":"80","author":"Rupasinghe","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diabet.2026.101744_bib0006","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/0956462416675107","article-title":"Integrase strand transfer inhibitor-associated diabetes mellitus: a case report","volume":"28","author":"Fong","year":"2017","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.diabet.2026.101744_bib0007","first-page":"19","article-title":"Raltegravir-associated diabetic ketoacidosis in a patient with HIV infection: a case report","volume":"43","author":"Horikawa","year":"2018","journal-title":"Tokai J Exp Clin Med"},{"key":"10.1016\/j.diabet.2026.101744_bib0008","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jac\/dkx365","article-title":"Dolutegravir-induced hyperglycaemia in a patient living with HIV","volume":"73","author":"McLaughlin","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diabet.2026.101744_bib0009","unstructured":"Duker A., Ntem-Mensah, Millman N, Jakharia N., Theppote A., Toeque M.G., et al. acute onset diabetic ketoacidosis\/hyperormolar hyperglycemic state in patients taking integrase strand transfer inhibitors. OFID; 20192019. p. S184."},{"key":"10.1016\/j.diabet.2026.101744_bib0010","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S2352-3018(20)30042-4","article-title":"Dolutegravir-associated hyperglycaemia in patients with HIV","volume":"7","author":"Lamorde","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.diabet.2026.101744_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab077","article-title":"Bictegravir-based antiretroviral therapy-associated accelerated hyperglycemia and diabetes mellitus","volume":"8","author":"Nolan","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diabet.2026.101744_bib0012","article-title":"Experience of dolutegravir-based antiretroviral treatment and risks of diabetes mellitus","volume":"10","author":"Hirigo","year":"2022","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.diabet.2026.101744_bib0013","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dme.13264","article-title":"Ketosis-prone atypical diabetes in Cameroonian people with hyperglycaemic crisis: frequency, clinical and metabolic phenotypes","volume":"34","author":"Lontchi-Yimagou","year":"2017","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabet.2026.101744_bib0014","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3390\/v17081108","article-title":"Safety, tolerability, and metabolic effects of long-acting cabotegravir and rilpivirine in HIV care: a Comprehensive review","volume":"17","author":"Bottanelli","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.diabet.2026.101744_bib0015","first-page":"503","article-title":"Hyperglycemia after dolutegravir-based antiretroviral therapy","volume":"14","author":"Hailu","year":"2021","journal-title":"Int Med Case Rep J"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363626000236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:18:58Z","timestamp":1777288738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363626000236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1262363626000236"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101744","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe hyperglycemia after initiation of long-acting cabotegravir in two antiretroviral treatment-controlled people with HIV","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101744"}}